Targeting acute myeloid leukemia CD34+ stem/progenitor cells with small molecule inhibitor MK-8776
Standard therapy or improving standard therapy can make the majority of acute myeloid leukemia (AML) patients partly or complete remission. However, the treatment often relapses from remission. A small fraction of leukemic stem cells (LSCs) are responsible for the accumulation of immature malignant cells in the bone marrow. LSCs were considered the ‘bad seeds’, it was showed that AML patients with LSCs enrichment have worse clinical outcomes [1]. Therefore, targeting LSCs by candidate drugs is crucial for AML therapies.
Source: Leukemia Research - Category: Hematology Authors: Hu Lei, Li Yang, Li Zhou, Ying Tong, Yingli Wu Tags: Correspondence Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Hematology | Leukemia | Stem Cell Therapy | Stem Cells